A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens (Q82758717)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 February 2010

Language	Label	Description	Also known as
English	A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens	scientific article published on 02 February 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jean-Yves Douillard

10

object named as

Jean-Yves Douillard

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Jaafar Bennouna

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Istvan Lang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Manuel Valladares-Ayerbes

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Katalin Boer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Antoine Adenis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Pilar Escudero

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Tae-You Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gillian M Pover

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Clive D Morris

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

2 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1021-1028

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20127139%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of Raf kinases in malignant transformation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience of MEK inhibitors in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent advances of MEK inhibitors and their clinical progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20127139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82758717&oldid=2221285414"